Macrocyclic compounds as STING agonists

A compound of Formula (Ia), its stereoisomer, or its pharmaceutically acceptable salt,

• wherein,
• R2 is independently selected from hydrogen, optionally substituted C1-C6 alkyl, and optionally substituted C3-C5 monocyclic cycloalkyl;
• ring A is independently selected from optionally substituted heterocyclyl, and optionally substituted heteroaryl;
• m is selected from 0, or 1;
• n is selected from 0, 1, or 2;
• when ‘alkyl’ is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, alkyl, perhaloalkyl, cycloalkyl, heterocyclyl, —N(R4)2, and —OR4;
• when ‘carbocycle’ or ‘cycloalkyl’ is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, alkyl, perhaloalkyl, —N(R4)2, and —OR4;
• when ‘heterocycle’ or ‘heterocyclyl’ is substituted, it is substituted with 1 to 4 substituents independently selected from oxo (═O), halogen, cyano, alkyl, perhaloalkyl, —OR4, —C(═O)OH, —OP(O)(OR4)2, —P(O)(OR4)2, —P(O)(OR4)R4a, —SO2R4a, —SO2NH2, —C(═O)N(H)R4, —C(═O)N(alkyl)R4, —N(H)C(═O)R4a, —N(H)R4, and —N(alkyl)R4;
• when the ‘heteroaryl’ group is substituted, it is substituted with 1 to 4 substituents selected from halogen, cyano, alkyl, perhaloalkyl, —O-alkyl, —O-perhaloalkyl, —N(alkyl)alkyl, —N(H)R4, —SO2-alkyl, —N(alkyl)C(═O)alkyl, —N(H)C(═O)alkyl, —C(═O)N(alkyl)alkyl, —C(═O)N(H)alkyl, —C(═O)NH2, —SO2N(alkyl)alkyl, —SO2N(H)alkyl, —SO2NH2, —C(═O)OH, —OP(O)(OR4)2, —P(O)(OR4)2, and —P(O)(OR4)R4a;
• each R4 is independently selected from hydrogen, alkyl, and cycloalkyl;
• and
• each R4a is independently selected from alkyl, and cycloalkyl.